0001714429-17-000003.txt : 20170928 0001714429-17-000003.hdr.sgml : 20170928 20170928094732 ACCESSION NUMBER: 0001714429-17-000003 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20170928 DATE AS OF CHANGE: 20170928 EFFECTIVENESS DATE: 20170928 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Caelum Biosciences, Inc. CENTRAL INDEX KEY: 0001714429 IRS NUMBER: 814861517 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-292630 FILM NUMBER: 171105862 BUSINESS ADDRESS: STREET 1: 2 GANSEVOORT STREET STREET 2: 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 BUSINESS PHONE: 781-652-4500 MAIL ADDRESS: STREET 1: 2 GANSEVOORT STREET STREET 2: 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 D/A 1 primary_doc.xml X0708 D/A LIVE 0001714429 Caelum Biosciences, Inc. 2 GANSEVOORT STREET 9TH FLOOR NEW YORK NY NEW YORK 10014 781-652-4500 DELAWARE FBIO Acquisition Corp. II None Corporation true 2015 Michael Spector 2 Gansevoort Street 9th Floor New York NY NEW YORK 10014 Executive Officer Director Lindsay A. Rosenwald c/o 2 Gansevoort Street 9th Floor New York NY NEW YORK 10014 Director Michael S. Weiss c/o 2 Gansevoort Street 9th Floor New York NY NEW YORK 10014 Director Jeffrey Paley c/o 2 Gansevoort Street 9th Floor New York NY NEW YORK 10014 Director Kenneth W. Cappell c/o 2 Gansevoort Street 9th Floor New Yor NY NEW YORK 10014 Director Martin Goldman c/o 2 Gansevoort Street 9th Floor New York NY NEW YORK 10014 Director William Natbony c/o 2 Gansevoort Street 9th Floor New York NY NEW YORK 10014 Director David Horin c/o 2 Gansevoort Street 9th Floor New York NY NEW YORK 10014 Executive Officer Biotechnology Decline to Disclose 06b true 0001714429-17-000002 2017-09-15 false true true false 0 National Securities Corporation 7569 National Securities Corporation 7569 410 Park Avenue 14th Floor New York NY NEW YORK 10022 All States false 10000000 9914000 86000 false 167 991400 0 In addition to the cash commission above, Issuer also issued warrants to purchase a number of shares of the Issuer's Common Stock equal to 10% of the aggregate amount of shares into which the Notes sold in the offering eventually convert. 0 Other than the payment of salaries and other compensation and benefits, no officer, director, or promoter will receive any payments from the proceeds of this offering. false Caelum Biosciences, Inc. /s/ Michael Spector Michael Spector Chief Executive Officer 2017-09-28